Guangdong Association of Clinical Trials
50
8
11
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
4.0%
2 terminated/withdrawn out of 50 trials
77.8%
-8.7% vs industry average
22%
11 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (50)
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
Role: lead
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Role: lead
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Role: lead
MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)
Role: lead
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Role: lead
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Role: lead
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Role: lead
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Role: lead
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Role: lead
A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
Role: lead
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Role: lead
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Role: lead
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
Role: lead
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Role: lead
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Role: lead
Phase II Umbrella Study Directed by Next Generation Sequencing
Role: lead
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Role: lead
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
Role: lead
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Role: lead
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Role: lead